Glaukos Highlights Expanding Innovation Portfolio at ASCRS 2026 Annual Meeting
Glaukos Corporation, a leader in ophthalmic pharmaceuticals and medical technologies, has announced its participation in the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, scheduled to take place from April 10–13, 2026, in Washington, D.C. The company will showcase a wide range of its cutting-edge technologies and research advancements aimed at improving outcomes in glaucoma, corneal disorders, and retinal diseases.
With a strong presence at booth #407, Glaukos is set to engage clinicians, researchers, and industry professionals through scientific presentations, educational programming, and product-focused discussions that highlight its growing role in transforming ophthalmic care.
Educational Symposium Spotlight: Introducing Epioxa™
A key highlight of Glaukos’ participation is its sponsored educational symposium, conducted in collaboration with ASCRS and EyeWorld. Titled:
“Introducing Epioxa™, the First and Only FDA-Approved Epithelium-On, Oxygen-Enriched Corneal Cross-Linking Treatment,”
the session will take place on Friday, April 10, from 12:00–1:00 p.m. ET at the Walter E. Washington Convention Center.
This symposium will feature a panel of respected experts, including:
- Dr. Brandon D. Ayres (Moderator)
- Dr. Kenneth A. Beckman
- Dr. Maanasa Indaram
- Matt Jensen, MBA
The session is expected to provide in-depth insights into Epioxa™, a novel advancement in corneal cross-linking technology designed to treat keratoconus and other corneal conditions. Unlike traditional approaches, Epioxa™ uses an epithelium-on method combined with oxygen enrichment, potentially offering improved patient comfort and procedural efficiency.
Scientific Presentations: Advancing Glaucoma and Corneal Care
Glaukos will present a robust lineup of scientific abstracts during the meeting, covering both glaucoma management and corneal health innovations.
Saturday, April 11, 2026
- 1:40–1:45 p.m. – Dr. Arkadiy Yadgarov
12-Month Outcomes of Standalone Third-Generation Trabecular Micro-Bypass Stents
This presentation will explore clinical outcomes in patients with open-angle glaucoma treated using advanced micro-bypass stent technology, emphasizing long-term intraocular pressure (IOP) control. - 2:01–2:06 p.m. – Dr. Michael B. Raizman
Design Review and Clinical Plan for Novel Keratoconus Screening Device
Attendees will gain insight into a next-generation diagnostic tool aimed at improving early detection and management of keratoconus.
Sunday, April 12, 2026
- 1:40–1:45 p.m. – Jasmin Kaur / Dr. Savak Teymoorian
12-Month Outcomes of Travoprost Intracameral Implant
This session will highlight findings from a single-center study evaluating the effectiveness of sustained drug delivery implants in patients with open-angle glaucoma or ocular hypertension. - 3:35–3:40 p.m. – Dr. Lisa K. Feulner
Real-World Outcomes of Combination Therapies
The presentation will focus on combining trabecular micro-bypass stents with intracameral implants or cataract surgery to enhance treatment outcomes.
On-Demand Poster Presentations
In addition to live sessions, Glaukos will feature several on-demand posters showcasing further research:
- Dr. Kenneth A. Beckman
Durability of Epithelium-On Corneal Cross-Linking in Keratoconus - Dr. John P. Berdahl
Safety and Efficacy of Combined Implant Therapies (3-Month Outcomes) - Dr. Christine N. Funke
Short-Term Outcomes of Third-Generation Stents with Drug Implants - Dr. Steven R. Sarkisian Jr.
Initial Results of Second-Generation Travoprost Intracameral Implant - Dr. Zachary D. Vest
Two-Year Outcomes of Micro-Bypass Procedures with Cataract Surgery
These presentations collectively underscore Glaukos’ commitment to generating clinical evidence that supports innovative treatment strategies across multiple ophthalmic conditions.
About the ASCRS Annual Meeting
The ASCRS Annual Meeting is widely regarded as one of the largest and most influential gatherings in the ophthalmology field. It brings together anterior segment surgeons, healthcare professionals, and industry leaders to exchange knowledge, review emerging technologies, and discuss best practices.
While Glaukos is an active participant and sponsor, it is important to note that all educational content at the meeting is independently developed by ASCRS program committees. The organization does not endorse or recommend specific products or treatments.
Product Focus: iDose® TR
One of Glaukos’ flagship innovations is iDose® TR, a long-duration intracameral implant designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Key Features:
- Constructed from medical-grade titanium
- Implanted directly into scleral tissue via the trabecular meshwork
- Delivers a continuous dose of travoprost (75 mcg)
- Enables 24/7 drug release through controlled diffusion
Indications:
iDose TR is indicated for reducing intraocular pressure (IOP) in patients diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Safety Considerations:
- Contraindicated in patients with ocular infections or certain corneal conditions
- Requires careful monitoring post-implantation
- May cause permanent iris pigmentation changes
Common Adverse Effects:
Reported side effects include increased IOP, eye inflammation, dry eye, visual disturbances, and ocular redness.
Product Focus: iStent infinite® Trabecular Micro-Bypass System
Another key innovation from Glaukos is the iStent infinite® Trabecular Micro-Bypass System, designed for patients with primary open-angle glaucoma who have not responded adequately to previous treatments.
Key Highlights:
- Implantable device that reduces intraocular pressure
- Suitable for patients with refractory glaucoma
- Designed to improve aqueous humor outflow
Usage Considerations:
- Not recommended for patients with angle-closure glaucoma or certain ocular abnormalities
- Requires preoperative gonioscopy to ensure proper placement
Safety and Monitoring:
- Classified as MR-Conditional (safe under specific MRI conditions)
- Postoperative monitoring is essential to maintain optimal IOP
Reported Adverse Events:
Common complications include:
- Elevated IOP
- Vision loss
- Ocular surface disease
- Inflammation
Commitment to Innovation and Patient Care
Glaukos continues to position itself at the forefront of ophthalmic innovation by combining advanced medical devices with pharmaceutical therapies. Its dual focus on minimally invasive surgical solutions and sustained drug delivery systems reflects a broader industry shift toward more patient-friendly and long-lasting treatments.
Through its participation in ASCRS 2026, the company aims to:
- Share new clinical evidence
- Educate physicians on emerging technologies
- Strengthen collaboration within the ophthalmology community
Forward-Looking Perspective
As with many healthcare innovators, Glaukos acknowledges that forward-looking statements regarding product development, regulatory approvals, and commercialization efforts are subject to uncertainties. These include factors such as:
- Regulatory timelines
- Market adoption
- Reimbursement dynamics
- Long-term safety and efficacy outcomes
The company emphasizes that while current data is promising, ongoing research and clinical validation remain critical.
Glaukos’ presence at the ASCRS 2026 Annual Meeting highlights its expanding influence in the field of ophthalmology. From groundbreaking treatments like Epioxa™ to sustained drug delivery systems such as iDose® TR and advanced implant technologies like iStent infinite®, the company is driving meaningful progress in the management of glaucoma and corneal diseases.
By showcasing its latest research and engaging with global experts, Glaukos continues to advance its mission of improving vision and quality of life for patients worldwide.
About Glaukos
Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
About Epioxa HD / Epioxa
Indication: EPIOXA™ HD (riboflavin 5’-phosphate ophthalmic solution) 0.239% and EPIOXA™ (riboflavin 5’-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O2n™ System and the Boost Goggles®.
Dosage and Administration: EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use. EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes after use. EPIOXA HD and EPIOXA are for use with the O2n System and Boost Goggles only. Refer to the O2n System Operator’s Manual and Boost Goggles User Guide for device instructions.
Contraindications: EPIOXA HD and EPIOXA are contraindicated in patients with known hypersensitivity to benzalkonium chloride or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens.
Warnings and Precautions: Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis.
Adverse Reactions:The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.
